EZH2 and acute myeloid leukemia: As a PRC2 inhibitor, DZNeP has been proven to induce anti-leukaemic effects by targeting EZH2 in AML.36 Here, we found that the migration of PCa cells was significantly inhibited by the combination of DZNeP and docetaxel.